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A B S T R A C T
Background
After surgery for localised breast cancer, radiotherapy (RT) improves both local control and breast cancer-specific survival. In patients
at risk of harbouring micro-metastatic disease, adjuvant chemotherapy (CT) improves 15-year survival. However, the best sequence of
administering these two types of adjuvant therapy for early-stage breast cancer is unclear.
Objectives
To determine the effects of different sequencing of adjuvant CT and RT for women with early breast cancer.
Search methods
An updated search was carried out in the Cochrane Breast Cancer Group’s Specialised Register (20 May 2011), MEDLINE (14
December 2011), EMBASE (20 May 2011) and World Health Organization (WHO) International Clinical Trials Registry Platform
(20 May 2011). Details of the search strategy and methods of coding for the Specialised Register are described in the Group’s module
in The Cochrane Library. We extracted studies that had been coded as ’early’, ’chemotherapy’ and ’radiotherapy’.
Selection criteria
We included randomised controlled trials evaluating different sequencing of CT and RT.
Data collection and analysis
We assessed the eligibility and quality of the identified studies and extracted data from the published reports of the included trials. We
derived odds ratios (OR) and hazard ratios (HR) from the available numerical data. Toxicity data were extracted, where reported. We
used a fixed-effect model for meta-analysis and conducted analyses on the basis of the method of sequencing of the two treatments.
Main results
Three trials reporting two different sequencing comparisons were identified. There were no significant differences between the various
methods of sequencing adjuvant therapy for local recurrence-free survival, overall survival, relapse-free survival and metastasis-free
survival based on 1166 randomised women in three trials. Concurrent chemoradiation increased anaemia (OR 1.54; 95% confidence
interval (CI) 1.10 to 2.15), telangiectasia (OR 3.85; 95% CI 1.37 to 10.87) and pigmentation (OR 15.96; 95% CI 2.06 to 123.68).
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Treated women did not report worse cosmesis with concurrent chemoradiation but physician-reported assessments did (OR 1.14; 95%
CI 0.42 to 3.07). Other measures of toxicity did not differ between the two types of sequencing. On the basis of one trial (244 women),
RT before CT was associated with an increased risk of neutropenic sepsis (OR 2.96; 95% CI 1.26 to 6.98) compared with CT before
RT, but other measures of toxicity did not differ.
Authors’ conclusions
The data included in this review, from three well-conducted randomised trials, suggest that different methods of sequencing CT and
RT do not appear to have a major effect on recurrence or survival for women with breast cancer if RT is commenced within seven
months after surgery.
P L A I N L A N G U A G E S U M M A R Y
Sequencing of chemotherapy and radiotherapy for women following surgery for early breast cancer
Both chemotherapy and radiotherapy reduce the risk of breast cancer recurring and the risk of dying from breast cancer. Generally,
these therapies are given after surgery but there is uncertainty about whether they should be given at the same time (concurrently) or
one after the other (sequentially). If they are used sequentially, the radiotherapy or the chemotherapy could be used first and concerns
have been expressed that the effectiveness of the therapy that is delayed might be reduced. However, it has also been suggested that
using chemotherapy and radiotherapy at the same time may be more toxic than keeping them separate. This review examined the
current evidence on the best way to administer chemotherapy and radiotherapy following breast-conserving surgery. We were able to
include three randomised trials. Two of these, with 853 women, assessed radiotherapy and chemotherapy given at the same time versus
chemotherapy given first followed by radiotherapy. The third trial randomised 244 women to radiotherapy followed by chemotherapy
versus chemotherapy followed by radiotherapy. The evidence produced by these three well-conducted trials suggests that recurrence of
a woman’s cancer and her chances of dying from breast cancer are similar regardless of the order of the treatments, provided that both
radiotherapy and chemotherapy are commenced within seven months of the surgery. The trials provided limited information regarding
adverse events, side effects or quality of life associated with the different sequences of treatment. The limited evidence available does
suggest that the frequency and severity of side effects of chemotherapy and radiotherapy are similar regardless of which sequence is
used. However, it should be noted that the women in these trials were treated, on average, in the early 2000s. As a result, the trials do
not assess the modern types of radiotherapy, and new types of chemotherapy (such as taxanes) or other drugs (such as Herceptin). We
will add relevant trials that include these more recent treatments to future updates of this review.
B A C K G R O U N D
Description of the condition
For women with localised breast cancer who undergo conservative
surgery or mastectomy, adjuvant radiotherapy (RT) reduces the
risk of local recurrence and improves breast cancer-specific survival
(EBCTCG 2011; Ragaz 2005). Adjuvant chemotherapy (CT) has
also been shown to improve 15-year survival (EBCTCG 2005b).
Description of the intervention
Current practices for the sequencing ofRTandCT include admin-
istering CT before RT, administering CT and RT concurrently,
or ’sandwiching’ RT in the middle of the CT course. It is not
clear which of these different sequences is the most effective for
women with early-stage breast cancer. It has been suggested that
the sequence of these two treatments may affect patient outcome
(Recht 1996). For example, a delay in initiating RT was found to
increase the risk of local recurrence (odds ratio (OR) 2.28, 95%
confidence interval (CI) 1.45 to 3.57) (Huang 2003). However,
a delay in commencing CT may also have a detrimental effect on
survival.
How the intervention might work
One published randomised trial initially found a non-significant
improvement in overall survival if CT was given first (Recht 1996)
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but longer follow-up did not reveal any difference in the rates of
local or distant recurrence or death between the two treatment
groups (Bellon 2001). Additionally, some non-randomised studies
have suggested that delaying RT while CT is administered first
could increase local recurrence rates (Buchholz 1993; Buchholz
1999; Buzdar 1993; Donato 2004; Hartsell 1995; Leonard 1995;
McCormick 1996;Meek1996; Recht 1991; Slotman 1994). Con-
versely, a delay in the administration of systemic CT while RT is
delivered could allow the proliferation of micro-metastatic disease
to an extent that it can no longer be dealt with adequately by the
CT.
Why it is important to do this review
Inmany parts of the world there are waiting lists for RT (Ash 2000;
Kenny 2004; MacKillop 1994; MacKillop 1995). The delivery
of CT first allows patients to start treatment and overcomes the
problem of RT waiting lists (Kenny 2004).
If a systematic review helps to resolve this uncertainty about the
relative effects of different sequences of CT and RT, it will assist in
making these choices. For example, if it shows that sequencing of
the two treatments makes little or no difference for cancer-related
outcomes such as survival and local recurrence, then choosing to
give CTfirstmay be preferable for both logistic reasons and patient
preference.
This 2011 review is an update of the Cochrane systematic review
first published in 2006.
O B J E C T I V E S
To determine the effects of different sequencing of RT and CT
for women with early-stage breast cancer who have been treated
surgically.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) evaluating different ways of
sequencing RT and CT were eligible. The comparison between
different sequences had to be unconfounded (i.e. the randomised
groups differed only in relation to the sequencing of the two treat-
ments). Trials incorporating the use of other adjuvant treatments,
such as monoclonal antibodies or hormonal therapy, were eligible
if these other treatments were applied in both groups in the RCT.
Published and unpublished studies were eligible.
Types of participants
Women with surgically treated, histologically confirmed early-
stage breast cancer who required both adjuvant CT and RT were
included. Early breast cancer included tumours classified as Union
for International Cancer Control (UICC) stage T1-3N0-1M0.
Surgery could comprise mastectomy, lumpectomy, wide local ex-
cision or quadrantectomy, with or without axillary dissection, ax-
illary sampling or sentinel node biopsy. Women who had previ-
ously received adjuvant therapy for breast cancer were not eligible.
Types of interventions
The following comparisons were eligible:
1. adjuvant RT followed by adjuvant CT versus adjuvant CT
followed by adjuvant RT;
2. adjuvant CT followed by adjuvant RT versus a ’sandwich
technique’ (when one or more courses of CT were followed by
RT, which was followed by further CT);
3. adjuvant CT followed by adjuvant RT versus concurrent
adjuvant CT and RT.
CT regimens included those delivered at standard doses (i.e. not
high dose), and could include drugs such as cyclophosphamide,
5-fluorouracil, anthracyclines, taxanes and other agents.
RT had to be delivered to the breast or chest wall, including or
excluding the supraclavicular fossa and axilla. Standard fractiona-
tion (1.8 to 3.0 Gray (Gy) per fraction) had to be used, delivering
40 to 61 Gy at the reference point. It could include a boost (using
electrons, interstitial therapy or external beam) or new techniques.
Types of outcome measures
Primary outcomes
• Local recurrence in the ipsilateral (i.e. same) breast and
cause-specific mortality. We defined local recurrence as including
recurrence in the ipsilateral breast (i.e. the breast in which cancer
had been diagnosed), the skin and parenchyma.
Secondary outcomes
• Overall survival.
• Distant metastases (in isolation or at the same time as local
recurrence).
• Relapse-free survival.
• Subsequent mastectomy.
• Harms, including acute and late effects of RT- and CT-
related toxicity.
• Ability to deliver the prescribed dose of CT and ability to
deliver the prescribed dose of RT. We set an arbitrary threshold
of 80% when assessing the ability to deliver the prescribed dose
of CT or RT.
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• Costs.
• Quality of life (QoL).
• Consumer preference.
Search methods for identification of studies
Electronic searches
For the original review published in 2006, we searched the
Cochrane Breast Cancer Group’s Specialised Register. Details of
the search strategy used by the Group to create this register and the
procedure used to code the references are described in the Group’s
module in The Cochrane Library. We extracted studies coded with
each of the three terms ’early’, ’chemotherapy’ and ’radiotherapy’
for consideration. We also conducted electronic searches of CEN-
TRAL (Issue 4, 2005), MEDLINE, CINAHL Current Contents
and the Science Citation Index.
For the 2011 review update, a further search on the Cochrane
Breast Cancer Group’s Specialised Register on 20 May 2011,
MEDLINE (14 December 2011; see Appendix 1 for the search
strategy), EMBASE (20 May 2011; see Appendix 2 for the search
strategy), Current Contents (December 2011), CINAHL (20 Jan-
uary 2012; see Appendix 3) and Science Citation Index (12March
2012; see Appendix 4).
We also searched registers of ongoing clinical trials for the
2011 update. These included the US clinical trials registry (
www.clinicaltrials.gov), the International Standard Randomised
Controlled Trial Number Register (www.controlled-trials.com/
isrctn) and the UKCCR National Register of Cancer Trials and
theWHO International Clinical Trials Registry Platform (20May
2011; see Appendix 5 for the search strategy).
We also searched other sources of unpublished trials (Greynet,
National Research Register) on 25 January 2012 and we contacted
researchers to ask if they were aware of any other trials on this
topic.
We checked for additional citations in eligible articles.
No language restrictions were employed.
Searching other resources
We handsearched a number of conference proceedings and pub-
lished abstracts. These included: 2001 Adjuvant Therapy for Pri-
mary Breast Cancer International Conference; Era of Hope, De-
partment of Defence Breast Cancer Research Program Meeting;
2001 and 2003: Primary Therapy of Early Breast Cancer; 6th and
7th Nottingham International Breast Cancer Meeting Conference
Report; 23rd and 24th Congress of the International Association
for Breast Cancer Research; 3rd and 4th Perspectives in Breast
Cancer Conference Report; 26th and 27th Annual San Antonio
Breast Cancer Symposium; 4th European Breast Cancer Confer-
ence; 94th and 95th American Association of Cancer Research;
AmericanSociety forClinicalOncology (1995 to2005); European
Society for Therapeutic and Radiation Oncology (2000 to 2004);
5th and 6th Milan Breast Cancer Conference; Australian Breast
Cancer Conference (2004); 27th and 28th Annual Symposium of
the American Society of Breast Disease; CDC Cancer Conference
(2003); British Cancer Meeting Report; Canadian Breast Cancer
Research Conference: Reasons for Hope.
Data collection and analysis
Selection of studies
All three review authors (BH, ML and DF) checked the titles and
abstracts retrieved by all searches. Each author assessed indepen-
dently the full text of the studies we thought might be relevant to
the review, resolving differences through discussion. We assessed
trials with the results masked. In cases where only limited data,
information on study methods or both was reported, we requested
further information from the authors of the original articles.
Data extraction and management
Two review authors (BH andML) performed data extraction, with
disagreements resolved by discussion. We contacted the original
authors for data from unpublished trials or published trials that
did not report data needed for this review. Data were entered into
Reference Manager software (RevMan 2011) for analyses. Where
possible, we extracted data on tumour stage, nodal status (patho-
logical), margin status, receptor status, hormonal manipulation,
treatment allocation and surgery performed. The information we
extracted on RT and CT included time from randomisation to
the start of RT and CT, duration of CT, duration of RT, radiation
dose and dose per fraction.We extracted outcome data for local re-
currence, distant metastases, deaths (cause-specific and all-cause),
treatment-related toxicity (including that related to acute and late
effects of RT and CT), costs of treatment, consumer preference
and quality of life.
Assessment of risk of bias in included studies
Two review authors (BH and ML) judged and graded each RCT
by using the Cochrane’s ’Risk of bias’ assessment tool as outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Grades given by each author were compared and
disagreements were resolved by discussion. The tool contains six
domains and each domain was assigned a judgement related to the
risk of bias. A judgement of ’low’ indicated a low risk of bias, ’high’
indicated a high risk of bias and ’unclear’ indicated an unknown
risk of bias. The six domains were:
1. sequence generation;
2. allocation concealment;
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3. blinding of participants, personnel and outcome assessors;
4. incomplete outcome data;
5. selective outcome reporting; and
6. other sources of bias.
The judgements of these domains for each RCT were reported in
the ’Risk of bias’ tables.
Measures of treatment effect
Dichotomous results (e.g. acute and late toxicity, cosmesis) were
presented as ORs with 95% CI (Deeks 2003). We used Mantel-
Haenszel methods to calculate pooled results (Greenland 1985;
Mantel 1959).
Time-to-event outcomes (e.g. local recurrence-free survival) were
presented as hazard ratios (HR).
Dealing with missing data
We contacted the original authors for data from unpublished trials
or published trials that did not report data needed for this review.
Assessment of heterogeneity
We assessed heterogeneity both visually and statistically using the
Chi2 test of heterogeneity (Altman 1992; Walker 1988). We did
not identify significant heterogeneity among the results of the trials
in the current analysis, but if heterogeneity is identified in updates
of this review, the reasons for it will be explored and we will make
a cautious attempt to explain it.
Data synthesis
We used the intention-to-treat principle in analysing data from
the trials and determined a weighted average treatment effect by
using the fixed-effect model to combine results (Mantel 1959) in
Review Manager software (RevMan 2011).
For the comparisons of concurrent versus sequential CT and RT,
raw data were not reported and therefore the HR and associated
statistics were calculated, where necessary, using an Excel spread-
sheet developed by the Matthew Sydes (Cancer Division) in col-
laboration with theMeta-analysis Group of theMRCClinical Tri-
als Unit, London (Sydes). This spreadsheet was used for the end
points of overall survival and relapse-free survival (Arcangeli 2006;
ARCOSEIN).
Similarly, for the comparison of RT then CT versus CT then RT,
raw data were not reported and therefore the HR and associated
statistics were calculated, where necessary, using an Excel spread-
sheet developed by the Matthew Sydes (Cancer Division) in col-
laboration with theMeta-analysis Group of theMRCClinical Tri-
als Unit, London (Sydes). In this case, the spreadsheet was used for
the end points of overall survival, distant metastases and relapse-
free survival (Bellon 2005).
Acute toxicity was dichotomised and we reported the OR with
95% CI. The authors used a four-point scale to report cosmesis
(see Table 1) and reported the proportion of women with excellent
cosmetic results (Bellon 2005).
For late toxicity (breast atrophy, breast fibrosis, telangiectasia, lym-
phoedema and cosmesis), the data were dichotomised and we re-
ported the Grade III/IV toxicity on the LENT-SOMA scale (see
Table 2). For pigmentation (not included in LENT-SOMA) we
reported those who had poor or very poor pigmentation (see Table
3). Late cosmetic toxicity was dichotomised and we reported the
proportion who had poor or very poor cosmesis on a five-point
scale (see Table 4).
If quality of life scores are available for future updates, we will
obtain the standard deviation and the mean to analyse the data. If
different scales are reported in the trials, we will use the standard-
ised mean difference to summarise data (Deeks 2003).
Subgroup analysis and investigation of heterogeneity
The current version of this review does not include any subgroup
analyses because of the lack of data. However, if sufficient data
become available in future updates, we may perform subgroup
analyses to investigate whether the effects of different sequences
of RT and CT differ depending upon nodal status, margin status,
receptor status, hormonal manipulation and tumour stage.
Sensitivity analysis
Sufficient data were not available to perform a sensitivity analysis.
In future updates, if adequate data are available, we would per-
form sensitivity analyses to assess the robustness of our results by
repeating the analysis with the following adjustments:
1. repeating the analysis excluding studies with high risk of
bias;
2. repeating the analysis each time excluding unpublished
trials.
R E S U L T S
Description of studies
Results of the search
After screening the titles and abstracts retrieved electronically and
by handsearching, we identified 441 reports for possible inclusion
in this review. Further screening of these reduced the number to
45 reports and, where possible, we obtained the full articles for
these. The results presented in these articles were masked and the
remaining text was assessed by two review authors (BH and ML).
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This revealed that 19 of the reports did not relate to RCTs ( Bellon
2004; Buzdar 1993; Cakir 2003; Denham 1995; Dubey 1999;
Faul 1998; Faul 2003; Fiets 2003; Garcia 1996; Hartsell 1995;
Hasbini 2000; Isaac 2002; Lamb 1999; Leonard 1995; Recht
1991; Rubens 1980; Sauer 1996; Stemmer 2003; Zambetti 1999)
and the treatments investigated in six were not eligible for this re-
view (Assersohn 1999; Bellantone 1998; Blomqvist 1992; Donato
2004; Wallgren 1996; Warner 1998). One study investigated dif-
ferent sequences of therapy but was confounded (and, therefore,
ineligible) because the CT regimens were different in the two ran-
domised groups (Rouesse 2002). Eighteen reports did relate to
four studies that appeared tomeet our inclusion criteria (Arcangeli
2006; Arcangeli 2004 (see Arcangeli 2006); Bellon 2002 (see
Bellon 2005); Bellon 2005; Bellon 2001; Calais 1998a; Calais
1998b; Calais 2002; Calais 2004; Fernando 2011 (see SECRAB);
ISRCTN84214355 (see SECRAB); Hardenbergh 1999; Pinnaro
2011; Recht 1996; Toledano 2006a (see ARCOSEIN); Toledano
2006b (see ARCOSEIN); Toledano 2007a (see ARCOSEIN);
Toledano 2007b (see ARCOSEIN)). One study (SECRAB) has
completed accrual, but has only been reported in abstract form
(Figure 1).
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Figure 1. Study flow diagram (updated search results to 14 December 2011).
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The eighteen reports that met the inclusion criteria related to
three separate studies because some of the trials had published
their results at different times, with different periods of follow-
up. In these cases we used the most recent publication as the
main source for this review, supplementing this with information
from earlier reports if necessary. Thus, for Bellon 2005, the main
source was the Bellon 2005 article, with four other publications
found for this trial (Bellon 2001; Bellon 2002; Hardenbergh
1999;Recht 1996). Similarly, for ARCOSEIN, our primary source
for data extraction was Calais 2004, with some information also
available in seven other publications (Calais 1998a; Calais 1998b;
Calais 2002; Toledano 2006a, Toledano 2006b; Toledano 2007a;
Toledano 2007b). For Arcangeli 2006, our primary source was
Pinnaro 2011, with some information available from Arcangeli
2006.
One report (Calais 1998b) required translation from French to
English, while another (Garcia 1996) required translation from
Spanish to English.
Of the three authors we contacted, two provided us with addi-
tional data on their studies (Arcangeli 2006; Rouesse 2002). We
are awaiting further information from one (Bellon 2005), as of
18/03/13, this had not been provided.
Included studies
Participants, follow-up and treatment regimens
The three RCTs, included in the updated version of this re-
view, randomised 1166 patients. Two studies (Arcangeli 2006;
ARCOSEIN), with 922 patients, compared concurrent CT and
RT with sequential administration of CT before RT. Arcangeli
2006 initially reported results at 65 months’ follow-up then again
after median follow-up of 111 months. ARCOSEIN reported at
60 months’ median follow-up, but late effects were reported at a
median of 6.7 years’ follow-up. First-generation chemotherapeu-
tic agents were used (i.e. no anthracyclines or taxanes).
Delay to start of radiotherapy
In the two studies (Arcangeli 2006; ARCOSEIN) that compared
concurrent CT and RT with sequential administration of CT
before RT, RT was started by a maximum of 161 days (about
5.3 months) in ARCOSEIN and by 210 days (seven months) in
Arcangeli 2006. In Bellon 2005, which compared RT followed
by CT to CT followed by RT, RT started by 84 days (about 2.8
months) after surgery.
The third RCT (Bellon 2005) compared RT followed by CT to
CT followed by RT in 244 patients. Bellon 2005 reported at a
median follow-up of 135 months. More information on the three
included studies can be found in the ’Characteristics of included
studies’ table. Anthracyclines were used but not taxanes.
Local recurrence
For the comparison of concurrent versus sequential CT and RT,
local recurrence was reported in Arcangeli 2006, but loco-regional
recurrence was reported in ARCOSEIN, so we were not able to
combine the results for this outcome. For the comparison of RT
then CT versus CT then RT, local recurrence was reported as first-
event data and we have contacted the authors (Bellon 2005) in
order to clarify this but await their reply.
Toxicity
Acute toxicity was assessed at one month after completion of RT
(ARCOSEIN) and was reported for 30% (214/716) of women
randomised. Grade III/IV acute toxicity was reported (however,
the scoring system was not given; ARCOSEIN). Acute haemato-
logical and skin toxicity was reported using the common toxicity
criteria (CTC) acute scoring system (Bellon 2005).
Late toxicity was assessed in ARCOSEIN and scored prospectively
at a median follow-up of 6.7 years in 29% (214/716) of those
women randomised. Two hundred and ninety-seven women from
the five larger participating institutions were asked to report for a
follow-up examination and 72% (214/297) of these women were
evaluated for late toxicity. Late toxicity was scored using the Late
Effects Normal Tissue Task Force (LENT)/Subjective, Objective,
Management, Analytic (SOMA) scale (validated scale) by an ob-
server blinded to the treatment arm (see Table 2). A personal five-
point scoring systemwas used to score pigmentation (not included
in the LENT/SOMA scale; see Table 3). Late toxicity was scored
as a single event at last follow-up. Breast oedema was defined as
“permanent swelling with an increased volume of the breast” and
fibrosis was detected by palpation, in comparison to the untreated
breast. Oedema was reported when the measurements differed.
Cardiac events were defined as myocardial infarction or clinical ev-
idence of congestive cardiac failure. Symptomatic radiation pneu-
monitis was characterised by a cough, fever and shortness of breath
that occurred two to nine months after completing RT.
In Bellon 2005, cardiac toxicity was assessed in 231/244 (95%)
women at a median follow-up of 53 months. Cardiac events were
defined as myocardial infarction or congestive cardiac failure. Late
toxicity data were extracted frommedical records and not prospec-
tively collected. Cellulitis was defined as the “inflammation of
the breast unresponsive to antibiotics” and lymphoedema was
recorded if therewas a descriptionof a “swollen or oedematous arm
in the treatment record” (no measurements were made at baseline
or of the contralateral arm). Brachial plexopathy was evaluated
only in those women who had regional nodal RT.
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Cosmesis
For the comparison of concurrent versus sequential CT and RT,
cosmetic outcomewas reported for 29%(214/716) ofwomen after
a median of 6.7 years’ follow-up. Seventy-two per cent (214/297)
of women from the five larger participating institutions who were
asked to report for a follow-up examination were evaluated for
cosmesis. The primary reason for refusal was a reluctance to attend
the hospital for clinical assessments. In ARCOSEIN, cosmesis was
evaluated both by the patient (using a five-point scale; Hoeller
2003) and physician blinded to treatment allocation. Physician-as-
sessed cosmesis was scored thus by an overall cosmetic satisfaction
score based on the comparison between the treated and untreated
breast (see Table 5) using “Harris’s classification modified by Bea-
dle” (Beadle 1984;Harris 1979; see Table 4). The second score was
derived using a detailed definition of how to score cosmesis satis-
faction (Fehlauer 2003). To lessen inter-observer variability, two
observers examined 40 patients and the ratings were reproducible.
There was “fair correlation” reported between the patient’s and
physician’s assessment of cosmesis. The two methods of scoring
cosmetic outcome by physicians were reported to be concordant
(ARCOSEIN).
For the comparison of RT then CT versus CT then RT, cosmetic
outcome was assessed in women without recurrence by a single
radiation oncologist at 18 to 30 months after treatment (31%
(76/244) of those women randomised; Bellon 2005). The authors
reported those in each group who had “excellent” cosmetic results
(i.e. a virtual absence of changes due to treatment) on a four-point
scale (see Table 1; Harris 1979). Figures were derived from the
percentages given in the text (Bellon 2005).
Excluded studies
See Excluded studies table.
Risk of bias in included studies
Allocation
All three included studies were randomised (Arcangeli 2006;
ARCOSEIN; Bellon 2005). Details about the methods of ran-
domisation were given in Arcangeli 2006 where the authors stated
a “balanced randomisation method” was used. It appears that the
studies were truly randomised and had a low risk of selection bias.
Blinding
In Arcangeli 2006, blinding was not reported for the assessors
of objective outcomes, if investigations such as mammograms or
bone scans were performed at different times in the two groups,
it may have introduced lead time bias. In ARCOSEIN, for the
subjective outcome of cosmesis, the assessor was blinded, which
minimises the risk of bias for this outcome. Detection bias was
less likely because there were pre-specified intervals for clinical
examination and investigations. Assessment of both late toxicity
and cosmetic outcome were blinded, which minimises the risk of
bias (ARCOSEIN). No mention was made of any blinding for
either objective or subjective outcomes in Bellon 2005, this means
the findings are at risk of bias.
Incomplete outcome data
All women randomised in the Arcangeli trial (Arcangeli 2006)
were included in the analysis. All women were analysed for the
primary end point. A total of 214 of 647 (33%) women were
included in the acute toxicity analysis in the ARCOSEIN trial
(ARCOSEIN). The remainder of the analyses were performed on
96% and 98% of the included women. Both Arcangeli 2006 and
ARCOSEIN were thought to be at low risk of attrition bias. In
Bellon 2005, those women lost to follow-up were described, and
the trial authors comment that an intention-to-treat analysis was
performed, but it can be seen from a table in the text that smaller
numbers were available for evaluation at five years, which suggests
there was a large amount of attrition in addition to the numbers
lost to follow-up reported in each arm. This makes the Bellon
trial at high risk of attrition bias (Bellon 2005).
Selective reporting
Wedid not review the protocols for any of the included trials. Cos-
metic outcome has not been reported (although the trial authors
indicated that they would in themethods) for Arcangeli 2006. For
ARCOSEIN and Bellon 2005, the end points indicated in the text
were all reported. The included studies are therefore at unclear risk
of reporting bias (Figure 2).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Effects of interventions
Concurrent treatment versus chemotherapy followed
by radiotherapy
For this comparison, first-generation chemotherapeutic agents
were used (i.e. no anthracyclines or taxanes).
There were two studies, enrolling 853 women, in this comparison
(Arcangeli 2006; ARCOSEIN). In the results presented, ratios
of treatment effects are given such that an OR or HR of less
than 1.0 would indicate a beneficial effect of concurrent treatment
compared with sequential treatment. The results for each outcome
are as follows.
• Local recurrence-free survival (ipsilateral): both studies
reported results for local recurrence. There were 14 such
recurrences in 602 randomised women. There was no evidence
to suggest that local recurrence -free survival differed when
concurrent CT/RT was compared with sequential at:
i) five-year follow-up: HR 0.96 (95% CI 0.14 to 6.82)
(Arcangeli 2006)(Analysis 1.1) or
ii) 10-year follow-up: HR 1.05 (95% CI 0.30 to 3.62)
(Arcangeli 2006). As data were available from one trial, testing
for heterogeneity was not appropriate (Analysis 1.1).
• Cause-specific survival: neither trial reported on this
outcome.
• Overall survival: did not differ when concurrent CT/RT
was compared with sequential at:
i) five year follow-up: HR 0.97; 95% CI 0.83 to 1.13
(Arcangeli 2006; ARCOSEIN; Analysis 1.4). No heterogeneity
was detected (I2 = 0%, P = 0.92);
ii) median follow-up of 111 months: HR 0.92; 95% CI
0.33 to 2.55 (Arcangeli 2006). As data were available from one
trial, testing for heterogeneity was not appropriate.
• Metastasis-free survival: 68/853 (8%) of the women in the
two trials combined had distant metastases diagnosed.
Metastasis-free survival did not differ when concurrent CT/RT
was compared with sequential at:
i) median follow-up of 60 to 65 months: HR 0.86; 95%
CI 0.60 to 1.24) (Arcangeli 2006; ARCOSEIN). No
heterogeneity was detected (I2 = 0%, P = 0.63);
ii) median follow-up of 111 months: HR 0.57; 95% CI
0.20 to 1.62) (Arcangeli 2006). As data were available from one
trial, testing for heterogeneity was not appropriate.
• Relapse-free survival did not differ when concurrent CT/
RT was compared with sequential at:
i) median follow-up of 50 to 65 months: HR 0.98; 95%
CI 0.84 to 1.15 (Arcangeli 2006; ARCOSEIN). No
heterogeneity was detected (I2 = 0%, P = 0.75) (Analysis 1.2);
ii) median follow-up of 111 months: HR 1.10; 95% CI
0.57 to 2.13 (Arcangeli 2006) (Analysis 1.2). As data were
available from one trial, testing for heterogeneity was not
appropriate.
• Mastectomy rate: no data.
• Harms and toxicity:
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i) acute toxicity: the Arcangeli 2006 report included the
comment that acute toxicity was “mild in both groups, with
infrequent moist desquamation in limited areas”. The other
study (ARCOSEIN), with 647 women, reported acute toxicity
for 214/647(33%) women studied. Anaemia increased with
concurrent CT/RT while nausea/vomiting and grade III/IV skin,
infection or oesophagitis did not (ARCOSEIN; see Table 6);
ii) late toxicity: in Arcangeli 2006, the authors indicated
that late toxicity is currently being evaluated and will be reported
separately. Late toxicity (including cosmesis) was reported in
detail for a subgroup of 214/647 (33%) of women studied
(ARCOSEIN). Telangiectasia and pigmentation were worse with
concurrent CT/RT but atrophy, fibrosis and lymphoedema did
not differ (ARCOSEIN; see Table 7). The women studied did
not report worse cosmetic outcome for overall cosmesis, skin
colour and scarring with concurrent CT/RT but the physician-
reported assessments indicated that cosmetic outcome was worse
with concurrent CT/RT (ARCOSEIN; see Table 8);
iii) no cardiac events occurred in the ARCOSEIN trial;
iv) no woman had symptomatic pneumonitis in the
ARCOSEIN trial;
v) one woman in each treatment arm developed acute
myelogenous leukaemia in the first 18 months after treatment in
the ARCOSEIN trial.
• Compliance:
i) ability to deliver the prescribed CT dose (compliance):
our arbitrary threshold of the delivery of at least 80% of the
prescribed CT was achieved for all women in both trials (OR
0.57; 95% CI 0.35 to 0.92) (Arcangeli 2006; ARCOSEIN)
(Analysis 1.3);
ii) ability to deliver the prescribed RT dose (compliance):
all patients in both randomised groups in the Arcangeli 2006
trial received 100% of their planned RT, and there was no
significant difference in the total dose delivered in both groups in
the ARCOSEIN trial.
• Costs: no data.
• QoL: no data.
• Consumer preference: no data.
Radiotherapy followed by chemotherapy versus
chemotherapy followed by radiotherapy
For this comparison, anthracyclines but not taxanes were used.
One study, including 244 women, was available for this compar-
ison (Bellon 2005). The following results are presented such that
an OR or HR of less than 1.0 favoured the group allocated to
receive RT first.
• Local recurrence-free survival (ipsilateral): local control was
reported but only as first-event data. We are awaiting a reply
from the author and will modify future updates of this review
when these data have been obtained (as of 18/03/13 this had not
been provided).
• Cause-specific survival at five years: no data.
• Overall survival did not differ between the two groups at:
i) five-year follow-up: HR 1.52; 95% CI 0.90 to 2.55
(Bellon 2005);
ii) 10-year follow-up: HR 1.20; 95% CI 0.76 to 1.89
(figures from the text; Bellon 2005).
• Metastasis-free survival did not differ between the two
groups when RT then CT versus CT then RT was compared at:
i) 5-follow-up: HR 1.62; 95% CI 1.00 to 2.61 (Bellon
2005);
ii) 11.2-year follow-up: HR 1.08; 95% CI 0.71 to 1.64
(Bellon 2005).
• Relapse-free survival did not differ between the two groups
when RT then CT versus CT then RT was compared at:
i) five-year follow-up: HR 1.37; 95% CI 0.88 to 2.14
(Bellon 2005);
ii) 11.2-year follow-up: HR 1.03; 95% CI 0.73 to 1.46
(Bellon 2005).
• Mastectomy rate: no data.
• Harms and toxicity:
i) acute toxicity: neutropenic sepsis was worse with RT
then CT, but other measures of acute toxicity (i.e. pneumonia,
skin and haematological toxicity) did not differ (see Table 9);
ii) late toxicity: pneumonitis, cosmesis and cellulitis
lymphoedema did not differ with RT then CT versus CT then
RT (see Table 10).
• Compliance:
i) ability to deliver the prescribed CT dose (compliance):
the RT first group received 81% of the planned CT dose, the CT
first group received 88% of the planned CT dose (P = 0.01;
Bellon 2005);
ii) ability to deliver the prescribed RT dose (compliance):
the median RT dose and duration of RT did not differ between
the two groups (no P value was reported; Bellon 2005).
• Costs: no data.
• QoL: no data.
• Consumer preference: no data.
D I S C U S S I O N
For women who elect to have breast-conservation surgery for early
breast cancer, achieving andmaintaining local control and improv-
ing survival are of paramount importance. The Early Breast Can-
cer Trialists’ Collaborative Group overview has shown the benefits
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of CT and RT as adjuvant treatments (EBCTCG 2011; EBCTCG
2005b) and this review set out to explore whether there is an opti-
mal sequencing of adjuvant CT and RT as part of the conservative
management of women with early breast cancer.
Summary of main results
We have been able to include data from three RCTs of two differ-
ent comparisons of sequencing. The comparisons are concurrent
versus sequential treatment (with CT before RT using first-gener-
ation chemotherapeutic agents, i.e. no anthracyclines or taxanes)
and RT followed by CT versus CT followed by RT (using anthra-
cyclines but no taxanes). In both comparisons the evidence sug-
gests that there are no major differences between the sequencing
techniques in regards to mortality and local or distant recurrence.
There is some evidence for differences in toxicity between sequenc-
ing techniques but most of the harms reported in the trials were
not significantly different between the randomised groups and CIs
were wide (see Table 6; Table 7; Table 8; Table 9; Table 10). We
found that there was disparity between the patient and physician
assessment of cosmesis with physicians reporting worse cosmetic
outcomes than the women themselves (ARCOSEIN; see Table
8). Others have also reported this difference in the perception of
cosmetic outcome (Thomson 2008). No data were available for
costs, quality of life or consumer preference. However, caution in
interpreting these results is advised as, given the low event rate for
some end points such as local recurrence, the statistical power for
detecting a clinically important risk difference in such outcomes
is very small.
Overall completeness and applicability of
evidence
The findings of this review provide reassurance that the general
practice of giving CT before RT is not detrimental in terms of
overall survival and toxicity in comparison with either the oppo-
site sequence or the concurrent administration of CT and RT.
However, some caveats are important in applying these results to
current practice. First, the treatments in the included trials were
given in the early 2000s on average and the CT regimens may not
be considered optimal today. In this case, first-generation chemo-
therapeutic agents were used (i.e. no anthracyclines or taxanes) in
Arcangeli 2006 and ARCOSEIN trials while anthracyclines were
used in the Bellon 2005 trial. Second, the surgical outcomes in
the trials might be considered unacceptable today. Positive surgical
margins are an independent predictor of local recurrence (Leong
2004) but women who had positive surgical margins were eligible
for the study of RT followed by CT versus CT followed by RT
(Bellon 2005). The standard of practice today would be to try to
ensure negative surgical margins were achieved before RT. Finally,
although the length of follow-up in the included trials is adequate
to detect differences in local recurrences, it is not yet long enough
to assess the effects on breast cancer mortality even with 10-year
data for two studies (Arcangeli 2006; Bellon 2005). Local recur-
rence after breast-conserving therapy reaches a peak at about two
years (Churn 2001) and continues at one per cent per year for at
least the next two decades (Kurtz 1987; Lippman 1995). Distant
recurrences and deaths from breast cancer take longer (EBCTCG
2011) and would not have been captured with the relatively short
follow-up of these trials. The length of follow-up is also short for
evaluation of some late toxicity namely, cardiac and second ma-
lignancy.
It has not been possible to answer some questions with this initial
version of the review. These include:
1. Harms, costs, patient preferences and impact on the QoL
The treatment-related toxicity differed little between the sequenc-
ing techniques. The women treated did not report worse cosmetic
outcome with concurrent CT/RT, but the physician-reported out-
comes for cosmesis were worse with concurrent CT/RT (Table 8).
There was no information regarding the QoL, women’s prefer-
ences or costs in the included trials. It has been shown that con-
current CT/RT can decrease a woman’s QoL but this seems sim-
ilar to that found with sequential therapy, and there may be an
advantage for concurrent therapy arising from its shorter duration
(Macquart-Moulin 1999).
2. The impact of new CT regimens and biological agents
The original standard CT regimen of CMF (cyclophosphamide,
methotrexate and 5-fluorouracil) has been superseded by anthra-
cycline-based regimens, particularly in high-risk younger women
(EBCTCG 2005b). In theory, these regimens should be less toxic
than the older regimens if delivered over the same or shorter time
period. Taxanes (paclitaxel and docetaxel) are new CT agents that
reduce the risk of death when used in the adjuvant setting for
women with early breast cancer (Henderson 2003; Martin 2005).
There is currently no information regarding the optimumsequenc-
ing of RT with taxanes. If taxanes were used sequentially with
standard CT agents (Henderson 2003), this would lead to an ex-
tended delay in starting RT, which has the potential to increase
the local recurrence rate. Reassuringly, in one trial in which RT
was delayed by the delivery of paclitaxel, there was a reduction in
local recurrence for those women who had undergone breast-con-
serving therapy and received paclitaxel (Henderson 2003). Fur-
thermore, new agents are continually being developed for treating
women with breast cancer (e.g. trastuzumab (Herceptin®) and
lapatinib), but the evidence to guide decisions about how these
should be sequenced with RT is limited. The delay to start of RT
in the included studies was less than seven months (see discussion
of Included Studies), more modern chemotherapeutic regimens
including taxanes can be delivered within this time frame, assum-
ing no delays in CT delivery.
3. The impact of new modes of RT
New techniques for breast irradiation after breast-conserving
surgery are emerging, such as partial breast irradiation using a va-
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riety of methods. These techniques generally seek to reduce the
amount of normal tissue radiated in order to reduce the incidence
of acute and late side effects. However, there is also one completed
trial (MA20) examining the role of nodal irradiation after conser-
vative surgery. Early release of data suggest improved disease-free
survival with the addition of nodal radiation. The potential im-
pact of this on clinical practice would be to increase the volume of
tissue radiated (Whelan 2011). Changes to the fractionation used
for RT after conservative surgery should also lead to less time being
needed for RT (Whelan 2002). If these techniques are effective,
this may allow RT to be delivered quickly and easily, before pro-
longed courses of CT. There is currently no reliable information
regarding the best sequencing of CT with these RT techniques.
4. Concurrent administration of modern CT and RT
The concurrent use of CT and RTminimises any delay in starting
RT and the concurrent use of CMF and RT does not appear to af-
fect objectively measured acute or late cosmetic outcomes or com-
plications (Arcangeli 2006; Faul 2003; Lamb 1999). There is some
non-randomised evidence that the concurrent use ofmoremodern
anthracycline CT and RT is associated with more high-grade skin
toxicity and higher hospitalisation rates, which have been deemed
by some to be unacceptable (Fiets 2003). We identified one on-
going study, which has completed accrual and has reported in ab-
stract form, which will provide information about the feasibility
and effectiveness of concurrent RT and anthracyclines (SECRAB).
Finally, some researchers maintain that the concurrent use of RT
and paclitaxel is feasible and have reported its use without dose
reductions, pneumonitis or brachial plexopathy (Formenti 2003).
However, others have reported pneumonitis rates as high as 14%
and have concluded that caution is required (Taghian 2001).
Quality of the evidence
We studied 1166 women randomised in three studies with follow-
up to 10 years. There is high-quality objective evidence related
to the toxicity and cosmetic outcomes when concurrent RT is
compared to sequential RT for early breast cancer. There is high-
quality evidence that local control and overall survival are similar
for concurrent CT and RT, RT followed by CT and CT followed
by RT for women with early breast cancer.
Potential biases in the review process
All three studies were at low risk of selection bias. In Arcangeli
2006, lack of blinding for objective outcomes may have intro-
duced lead-time bias. In ARCOSEIN, blinding reduced the risk of
bias for the subjective outcomes of cosmesis and toxicity. Blinding
was not mentioned in Bellon 2005, which makes the evaluation of
objective outcomes (cosmesis and toxicity) at risk of bias. While
Arcangeli 2006 and ARCOSEIN were at low risk of bias for at-
trition, Bellon 2005 was at high risk of bias. As we were not able
to review protocols, the risk of selective reporting bias for all three
studies was unclear (Figure 2).
Agreements and disagreements with other
studies or reviews
We found no other systematic reviews or meta-analyses on this
topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence from three well-conducted RCTs indicated that local
control and overall survival is similar for concurrent CT and RT,
RT followed by CT, and CT followed by RT for women with early
breast cancer when the RT was commenced within seven months
after surgery (as this was the maximum delay in the included stud-
ies). These data were based on the use of first-generation chemo-
therapeutic agents (thus excluding anthracyclines and taxanes) for
the comparison of concurrent versus sequential CT.
Implications for research
RCTs are needed to assess the relative effects of sequencing tra-
ditional and new RT techniques with new CT regimens and bi-
ological therapies, including taxanes and Herceptin. Future trials
should collect data on costs, QoL, and patient preference; as well
as on local and distant recurrence, cause specific mortality and
harms.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arcangeli 2006
Methods Accrual: January 1997 to November 2002
Single centre, Italy
Randomisation balanced to strata: method not specified
Stratified according to tumour diameter, age and lymph node status
Baseline: no differences
Power calculation
Participants 206 women with breast cancer (pT1-2N0-1M0), who had quadrantectomy and axillary
dissection, negative margins, no previous radiotherapy (RT)
Aged 18 to 76 years
Interventions Experimental: concurrent (cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
synchronous with RT)
Control: sequential (CMF then RT at 7 months)
CMF: included cyclophosphamide 600 mg/m2 intravenously, days 1, 8, every 28 days,
6 cycles
RT: 50 Gy/20 fractions + boost 10 Gy/6 fractions
Tamoxifen: oestrogen-receptor positive women received tamoxifen for 5 years after com-
pletion of CT and RT. 65/106 in the CT/RT arm and 53/100 in the CT then RT arm
were oestrogen-receptor positive, but the numbers of women who received tamoxifen
were not reported
Outcomes Primary: breast recurrence-free interval
Other: overall survival, locoregional recurrence, distant metastases, toxicity
Notes Median follow-up: 111 months
All randomised patients used in time-to-event analyses
First-generation chemotherapeutic agents used (i.e. no anthracyclines or taxanes)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “were randomised” (abstract, para-
graph 2)
Quote: “were randomised” (methods and
materials, paragraph 3, page 162)
Quote: “after stratification, patients were
assigned to the study group with a balanced
randomisation method, to ensure closely
balanced patient numbers in each group
according to the planned strata” (statistical
methods, paragraph 5, page 163)
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Arcangeli 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Not mentioned, uncertain whether done,
therefore uncertain risk of bias
Blinding (performance bias and detection
bias)
Objective outcomes
Unclear risk Not mentioned, probably not done. There
is no information given about follow up in
each of the 2 arms, or prescribed intervals
for investigations
Quote: “Baseline mammogram was ob-
tained in the first year after RT” (paragraph
15, page 67)
Thismay cause a high risk of bias, e.g. if un-
blinded investigators performed investiga-
tions (mammograms or bone scans) at dif-
ferent time intervals for women in different
arms, it could introduce lead time bias
Blinding of participants and personnel
(performance bias)
Objective outcomes
Unclear risk Not mentioned, but not possible to do, as
the 2 treatment arms differed greatly, prob-
ably of little consequence for objective out-
comes, and as there were no patient-related
outcomes, it is unlikely to be a high risk of
bias
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Cosmetic outcome was patient-assessed
(not possible to blind). This is unlikely to
have introduced bias
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Not mentioned, probably not done, it
would be difficult to do given the differ-
ences in the treatment arms. Unlikely to be
a high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk N = 206
Arm 1 = 106
Arm 2 = 100
All patients included in the analysis
None lost to follow-up
Selective reporting (reporting bias) Unclear risk Outcomes specified in the methods/pro-
tocol:
1. breast recurrence-free survival
2. overall survival
3. loco-regional recurrence
4. distant metastases
5. toxicity (using European
Organization for Research and Treatment
of Cancer/Radiation Therapy Oncology
Group (EORTC/RTOG) scoring system)
6. whether or how concurrent
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Arcangeli 2006 (Continued)
chemotherapy (CT) administration was
influenced by RT
7. whether or how RT administration
influenced by concurrent CT
8. cosmetic result
Outcomes actually reported in the pa-
per:
1. breast recurrence-free survival
2. metastasis-free survival
3. distant failure
4. overall survival
5. site of first recurrence
6. numbers of events in each group
7. breast recurrences
8. nodal recurrences
9. distant metastases
10. contralateral breast cancer or second
primary other site
11. toxicity - acute local toxicity (not
quantified)
12. RT compliance, dose delivered, any
breaks in RT
13. CT compliance, number of cycles
received, mean dose intensity
We were unable to review the protocol,
therefore it has been designated as unclear
risk of bias
ARCOSEIN
Methods Accrual: March 1996 to May 2000
Multicentre, France
Patients were stratified according to axillary status
Randomisation method not specified
Baseline imbalances: the 2 groupswere balanced regarding age, stage, performance status,
histology, hormonal receptors, tumour margins, in situ components and axillary status
Participants 647 women who had breast-conserving surgery for breast cancer
Median age: experimental group 58.6 years, control group 49.5 years
Interventions Experimental: chemotherapy (CT) plus radiotherapy (RT) concurrently
Control: CT followed by RT sequentially
CT: 5-fluorouracil 500 mg/m2, mitoxantrone 12 mg/m2, cyclophosphamide 500 mg/
m2: 6 cycles given at 21 days
Post- or peri-menopausal women with oestrogen-receptor-positive tumours or proges-
terone-receptor-positive tumours (or both) received tamoxifen; this was started during
or after RT at the discretion of the treating physician. 171/352 women in the CT/RT
arm and 160/343 women in the CT followed by RT arm received tamoxifen
RT: 50 Gy with or without 10 to 20 Gy boost to tumour bed. Boost given if there were
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ARCOSEIN (Continued)
factors for local recurrence (not specified): given during cycles 1 to 3 of CT (experimental)
or after CT (control)
Outcomes Local and regional recurrences, distant metastases, secondary cancers, overall survival,
acute toxicity, protocol adherence, antitumour effects
Notes Median follow-up: 60 months
First-generation chemotherapeutic agents used (i.e. no anthracyclines or taxanes)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of generating randomisation se-
quence was not specified
Quote: “phase III randomised” (abstract,
paragraph 1, page 405)
Quote: “were randomly assigned”
Allocation concealment (selection bias) Low risk Concealment of randomisation was not
specified, but appears to have been central,
so probably was concealed
Quote: “random assignment was per-
formed at the Biostatistics Unit at ..” (pa-
tients and methods, paragraph 11, page
406)
Blinding (performance bias and detection
bias)
Objective outcomes
Low risk Not mentioned, probably not done, un-
likely to have introduced bias as no patient-
reported outcomes included
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Not mentioned, probably not done, un-
likely to have introduced bias, it would be
difficult to blind personnel, given the na-
ture of the interventions. Unlikely to be a
source of bias
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: “..the Physician in charge of the
evaluation did not have knowledge of the
patient’s (self ) assessment was kept blinded
to treatment arm” (methods and materi-
als, paragraph 17, page 67). This makes the
assessment of subjective outcomes such as
cosmesis at low risk of bias
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Blinding not mentioned, but risk of bias re-
duced by having pre-specified time points
for clinical examination and mammogra-
phy
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ARCOSEIN (Continued)
Quote: “all patients were monitored rou-
tinely for at least five years after RT. Our
follow-up consisted of a twice-yearly clin-
ical examination, and an annual mammo-
gram” (paragraph 14, page 67)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk i) Cosmetic outcome assessment blinded to
treatment arm
Quote: “toxicity assessment, blinded to
treatment allocation…” (paragraph 16,
page 67)
Quote: “To avoid bias, the physician in
charge of the evaluation (A.H.T.) did not
have knowledge of the patient’s assessment
and was kept blinded to the treatment arm”
(paragraph 19, page 67)
Cosmetic outcome assessed by a blinded
doctor, therefore there was low risk of bias
with this objective outcome
ii) Late toxicity: assessment was blinded to
treatment allocation
iii) Quote: “this toxicity assessment,
blinded to treatment allocation” (para-
graph 15, page 67)
Incomplete outcome data (attrition bias)
All outcomes
Low risk CT plus RT arm: 15 women found to be
ineligible and excluded
CT followed by RT arm: 6 found ineligible
CT plus RT arm: 10 women lost to follow-
up
CT followed by RT arm: 3 lost to follow-
up
716 women were randomised, 352 in the
CT plus RT arm and 343 in the CT fol-
lowed byRT armwere included in the anal-
ysis. The primary end point (disease-free
survival) was an intention-to-treat analysis
so 358 women were analysed for this end
point in each arm. The authors described
the reasons the women were found to be
ineligible, it was felt to be at low risk of bias
Selective reporting (reporting bias) Unclear risk Outcomes specified in the methods/pro-
tocol
Primary end point:
1. disease-free survival
Secondary end point:
1. incidence of adverse effects
2. cosmesis
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ARCOSEIN (Continued)
3. overall survival
Outcomes actually reported in the pa-
per:
1. compliance
2. median CT dose
3. median time to complete CT
4. dose-intensity of CT
5. RT dose
6. RT interruptions
7. acute toxicity (oesophagitis, acute
systemic symptoms, nausea/vomiting,
anaemia)
8. late toxicity (subcutaneous fibrosis,
telangiectasia, skin pigmentation, breast
atrophy, pain, breast oedema,
lymphoedema, acute myeloid leukaemia)
9. disease-free survival at 5 years
10. local recurrence-free survival
11. metastasis-free survival
12. overall survival
13. rates of death
14. local recurrence
15. regional or distant metastases as first
site of recurrence
16. breast cancer deaths
17. alive, no evidence of disease
We were not able to review the protocol
Bellon 2005
Methods Accrual: June 1984 to October 1992
Multicentre, USA
Randomisation method not specified
Stratified by: number of nodes involved, menopausal status
Baseline imbalances: radiotherapy (RT) first group had more patients with tumour size
1 to 2 cm and intraductal component. Had fewer patients with boost dose of 16 Gy or
higher
Power calculation
Participants 244 women with stage I or II breast cancer who had undergone conservative therapy
(excision of all gross disease and level I/II axillary dissection)
Aged 20 to 68 years
Interventions Experimental: RT then chemotherapy (CT)
Control: CT then RT
CT: CAMFP 4 cycles, given every 21 days (cyclophosphamide 500 mg/m2, doxorubicin
45 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 500 mg/m2, prednisone 40 mg/m2,
leucovorin 10 mg/m2, orally, 4 times per day, days 2 to 4)
Initially, no women was to receive tamoxifen, but in September 1988, a protocol amend-
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Bellon 2005 (Continued)
ment was made, so that all women with oestrogen-receptor-positive tumours were to
receive tamoxifen for 5 years (after completion of all CT and RT). 7/122 women in the
RT then CT arm and 11/122 women in the CT then RT arm received tamoxifen
RT: 45 Gy/25 fractions + 16- to 18-Gy boost
Outcomes Overall survival (10 years), event-free survival, local recurrence, distant/regional recur-
rence. Toxicity outcomes (cardiac events, lymphoedema and brachial plexopathy) re-
ported as retrospective data from chart review
Notes Median follow-up: 135 months (range 17 to 196)
No taxanes were used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details about method of random se-
quence generation given. Quote: “prospec-
tive randomised trial” (abstract, page 1934)
Quote: “were randomly assigned” (ab-
stract, paragraph 2, page 1934)
Quote: “were randomly assigned” (patients
and methods, paragraph 3, page 1935)
Allocation concealment (selection bias) Low risk It was not specified that allocation was con-
cealed, but it probably was, therefore at low
risk of bias.Quote: “patientswere registered
centrally” (statistical analysis, paragraph 5,
page 1357)
Blinding (performance bias and detection
bias)
Objective outcomes
Low risk Not mentioned, probably not done. It
would be quite difficult to do, given the
differences in the treatment arms. Probably
not important, as no patient-reported out-
comes
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Not mentioned, probably not done. It
would be quite difficult to do, given the
differences in the treatment arms. Probably
not important
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Not mentioned, probably not done. This
may introduce bias, especially in assess-
ment of toxicity. No pre-specified follow-
up schedule or investigations schedule,
which may introduce bias in detection of
local recurrence and distant metastases
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Bellon 2005 (Continued)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Quote: “cosmetic outcome assessed in pa-
tients without recurrence who were seen
in follow up by a radiation oncologist...”
There is no mention of blinding of the ra-
diation oncologist who evaluated cosmesis,
which make these findings at high risk of
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk RT then CT arm: 4 lost to follow-up
CT then RT arm: 5 lost to follow-up
Comment that intention-to-treat analysis
performed, but see from Table 2, that
smaller numbers were available for evalua-
tion at 5 years, which suggests there was a
large amount of attrition in addition to the
numbers
Selective reporting (reporting bias) Low risk Outcomes specified in the methods/pro-
tocol
1. time to first recurrence
2. time to distant metastases
3. overall survival
4. contralateral breast cancer
5. second non-breast cancer primary
6. local recurrence
7. distant metastases
8. local recurrence
9. regional recurrence
10. other failures (contralateral breast
cancer, other primaries (non-breast
cancer), death from other causes
Outcomes actually reported in the pa-
per:
1. distant metastases and freedom from
distant metastases
2. deaths
3. any recurrence
4. overall survival
5. time to first recurrence
6. time to distant recurrence
7. site of first recurrence
8. local recurrence
9. breast cancer recurrence
10. contralateral breast cancer
11. second (non-breast cancer)
malignancy
12. median dose CT delivered
13. median time required to complete
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CT
14. median RT dose
15. median duration RT
16. acute toxicity
17. haematological
18. fever or neutropenia requiring
hospitalisation
19. pneumonia pneumonitis
20. moist/extensive desquamation
21. cosmesis assessed in cohort of 39
women seen at the joint centre
The protocol was not reviewed
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Assersohn 1999 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy, as required by our inclusion
criteria
Bellantone 1998 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy, as required by our inclusion
criteria. Treatments were given before surgery rather than after surgery, as required by our inclusion criteria
Bellon 2004 Not a randomised trial
Blomqvist 1992 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy, as required by our inclusion
criteria
Buzdar 1993 Not a randomised trial
Cakir 2003 Not a randomised trial
Denham 1995 Not a randomised trial
Donato 2004 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy in post-surgery patients with
early stage breast cancer, as required by our inclusion criteria
Dubey 1999 Not a randomised trial
Faul 1998 Not a randomised trial
Faul 2003 Not a randomised trial
Fiets 2003 Not a randomised trial
Garcia 1996 Not a randomised trial
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Hartsell 1995 Not a randomised trial
Hasbini 2000 Not a randomised trial
Isaac 2002 Not a randomised trial
Kim 2010 Surgery involved mastectomy
Lamb 1999 Not a randomised trial
Leonard 1995 Not a randomised trial
Recht 1991 Not a randomised trial
Rouesse 2002 Randomised trial, but confounded by different chemotherapy regimens in the 2 study groups
Rubens 1980 Not a randomised trial
Sauer 1996 Not a randomised trial
Stemmer 2003 Not a randomised trial
Wallgren 1996 Sequences of adjuvant chemotherapy and adjuvant radiotherapy were not consistent with our inclusion criteria
Warner 1998 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy, as required by our inclusion
criteria
Zambetti 1999 Not a randomised trial
Characteristics of studies awaiting assessment [ordered by study ID]
SECRAB
Methods Multicentred randomised controlled trial
Participants Women with histological diagnosis of invasive breast cancer who had undergone wide local excision or mastectomy
Interventions Sequential chemotherapy/radiotherapy and ’sandwich’ chemotherapy/radiotherapy/chemotherapy
Outcomes Primary end point: local recurrence at 5 years
Secondary end points: distant metastases; relapse rates; overall survival at 5, 10 and 15 years. A sample of 300 will be
studied for toxicity, cosmesis and quality of life
Notes ISRCTN 84214355
Multicentred randomised controlled trial
Setting: UK
Accrual completed
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D A T A A N D A N A L Y S E S
Comparison 1. Concurrent versus sequential (chemotherapy first)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Local recurrence-free survival 1 Hazard Ratio (95% CI) Subtotals only
1.1 Local recurrence-free
survival at 5 years
1 0 Hazard Ratio (95% CI) 0.96 [0.14, 6.82]
1.2 Local recurrence-free
survival at 10 years
1 0 Hazard Ratio (95% CI) 1.05 [0.30, 3.62]
2 Relapse-free survival 2 Hazard Ratio (95% CI) Subtotals only
2.1 Relapse-free survival HR
at 5 years
2 0 Hazard Ratio (95% CI) 0.98 [0.84, 1.15]
3 Compliance with chemotherapy 2 901 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.35, 0.92]
4 Overall survival 2 Hazard Ratio (95% CI) Subtotals only
4.1 Overall survival at five
years
2 901 Hazard Ratio (95% CI) 0.97 [0.83, 1.13]
5 Metastasis-free survival 2 Hazard Ratio (95% CI) Subtotals only
5.1 Metastasis-free survival at
5 years
2 0 Hazard Ratio (95% CI) 0.86 [0.60, 1.24]
5.2 Metastasis-free survival at
10 years
1 0 Hazard Ratio (95% CI) 0.57 [0.20, 1.62]
Comparison 2. Radiotherapy then chemotherapy versus chemotherapy then radiotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 1 Hazard Ratio (95% CI) Subtotals only
1.1 Overall survival at 5 years 1 0 Hazard Ratio (95% CI) 1.52 [0.90, 2.55]
1.2 Overall survival at 10 years 1 0 Hazard Ratio (95% CI) 1.20 [0.76, 1.89]
2 Metastasis-free survival 1 Hazard Ratio (95% CI) Subtotals only
2.1 Distant metastases at 5
years
1 0 Hazard Ratio (95% CI) 1.62 [1.00, 2.61]
2.2 Distant metastases at 10
years
1 0 Hazard Ratio (95% CI) 1.08 [0.71, 1.64]
3 Relapse-free survival 1 Hazard Ratio (95% CI) Subtotals only
3.1 Relapse-free survival at 5
years
1 0 Hazard Ratio (95% CI) 1.37 [0.88, 2.14]
3.2 Relapse-free survival at 10
years
1 0 Hazard Ratio (95% CI) 1.03 [0.73, 1.46]
4 Cosmesis 1 77 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.51, 3.31]
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Analysis 1.1. Comparison 1 Concurrent versus sequential (chemotherapy first), Outcome 1 Local
recurrence-free survival.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 1 Concurrent versus sequential (chemotherapy first)
Outcome: 1 Local recurrence-free survival
Study or subgroup Concurrent Sequential Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Local recurrence-free survival at 5 years
Arcangeli 2006 0/0 0/0 100.0 % 0.96 [ 0.14, 6.82 ]
Subtotal (95% CI) 0 0 100.0 % 0.96 [ 0.14, 6.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Local recurrence-free survival at 10 years
Arcangeli 2006 0/0 0/0 100.0 % 1.05 [ 0.30, 3.62 ]
Subtotal (95% CI) 0 0 100.0 % 1.05 [ 0.30, 3.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
0.01 0.1 1 10 100
Favours concurrent Favours sequential
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Analysis 1.2. Comparison 1 Concurrent versus sequential (chemotherapy first), Outcome 2 Relapse-free
survival.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 1 Concurrent versus sequential (chemotherapy first)
Outcome: 2 Relapse-free survival
Study or subgroup Concurrent Sequential Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Relapse-free survival HR at 5 years
Arcangeli 2006 0/0 0/0 5.0 % 1.00 [ 0.49, 2.04 ]
ARCOSEIN 0/0 0/0 95.0 % 0.98 [ 0.83, 1.16 ]
Subtotal (95% CI) 0 0 100.0 % 0.98 [ 0.84, 1.15 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours concurrent Favours sequential
Analysis 1.3. Comparison 1 Concurrent versus sequential (chemotherapy first), Outcome 3 Compliance
with chemotherapy.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 1 Concurrent versus sequential (chemotherapy first)
Outcome: 3 Compliance with chemotherapy
Study or subgroup Concurrent Sequential Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arcangeli 2006 99/106 95/100 14.1 % 0.74 [ 0.23, 2.43 ]
ARCOSEIN 309/352 319/343 85.9 % 0.54 [ 0.32, 0.91 ]
Total (95% CI) 458 443 100.0 % 0.57 [ 0.35, 0.92 ]
Total events: 408 (Concurrent), 414 (Sequential)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours concurrent Favours sequential
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Analysis 1.4. Comparison 1 Concurrent versus sequential (chemotherapy first), Outcome 4 Overall survival.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 1 Concurrent versus sequential (chemotherapy first)
Outcome: 4 Overall survival
Study or subgroup Concurrent Sequential Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Overall survival at five years
Arcangeli 2006 0/106 0/100 1.8 % 0.71 [ 0.22, 2.25 ]
ARCOSEIN 0/352 0/343 98.2 % 0.98 [ 0.83, 1.14 ]
Subtotal (95% CI) 458 443 100.0 % 0.97 [ 0.83, 1.13 ]
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours concurrent Favours sequential
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Analysis 1.5. Comparison 1 Concurrent versus sequential (chemotherapy first), Outcome 5 Metastasis-free
survival.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 1 Concurrent versus sequential (chemotherapy first)
Outcome: 5 Metastasis-free survival
Study or subgroup Concurrent Sequential Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Metastasis-free survival at 5 years
Arcangeli 2006 0/0 0/0 10.5 % 0.66 [ 0.21, 2.04 ]
ARCOSEIN 0/0 0/0 89.5 % 0.89 [ 0.60, 1.31 ]
Subtotal (95% CI) 0 0 100.0 % 0.86 [ 0.60, 1.24 ]
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
2 Metastasis-free survival at 10 years
Arcangeli 2006 0/0 0/0 100.0 % 0.57 [ 0.20, 1.62 ]
Subtotal (95% CI) 0 0 100.0 % 0.57 [ 0.20, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
0.01 0.1 1 10 100
Favours concurrent Favours sequential
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Analysis 2.1. Comparison 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy,
Outcome 1 Overall survival.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy
Outcome: 1 Overall survival
Study or subgroup RT then CT CT then RT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Overall survival at 5 years
Bellon 2005 0/0 0/0 100.0 % 1.52 [ 0.90, 2.55 ]
Subtotal (95% CI) 0 0 100.0 % 1.52 [ 0.90, 2.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
2 Overall survival at 10 years
Bellon 2005 0/0 0/0 100.0 % 1.20 [ 0.76, 1.89 ]
Subtotal (95% CI) 0 0 100.0 % 1.20 [ 0.76, 1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
0.01 0.1 1 10 100
Favours RT then CT Favours CT then RT
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Analysis 2.2. Comparison 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy,
Outcome 2 Metastasis-free survival.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy
Outcome: 2 Metastasis-free survival
Study or subgroup RT then CT CT then RT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Distant metastases at 5 years
Bellon 2005 0/0 0/0 100.0 % 1.62 [ 1.00, 2.61 ]
Subtotal (95% CI) 0 0 100.0 % 1.62 [ 1.00, 2.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
2 Distant metastases at 10 years
Bellon 2005 0/0 0/0 100.0 % 1.08 [ 0.71, 1.64 ]
Subtotal (95% CI) 0 0 100.0 % 1.08 [ 0.71, 1.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 1.57, df = 1 (P = 0.21), I2 =36%
0.01 0.1 1 10 100
Favours RT then CT Favours CT then RT
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Analysis 2.3. Comparison 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy,
Outcome 3 Relapse-free survival.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy
Outcome: 3 Relapse-free survival
Study or subgroup RT then CT CT then RT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Relapse-free survival at 5 years
Bellon 2005 0/0 0/0 100.0 % 1.37 [ 0.88, 2.14 ]
Subtotal (95% CI) 0 0 100.0 % 1.37 [ 0.88, 2.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
2 Relapse-free survival at 10 years
Bellon 2005 0/0 0/0 100.0 % 1.03 [ 0.73, 1.46 ]
Subtotal (95% CI) 0 0 100.0 % 1.03 [ 0.73, 1.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
0.01 0.1 1 10 100
Favours RT then CT Favours CT then RT
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Analysis 2.4. Comparison 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy,
Outcome 4 Cosmesis.
Review: Sequencing of chemotherapy and radiotherapy for early breast cancer
Comparison: 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy
Outcome: 4 Cosmesis
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bellon 2005 26/39 23/38 100.0 % 1.30 [ 0.51, 3.31 ]
Total (95% CI) 39 38 100.0 % 1.30 [ 0.51, 3.31 ]
Total events: 26 (Experimental), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. Harris’s classification
Cosmetic score
Excellent
Good
Fair
Poor
Table 2. LENT/SOMA scoring scale
Type of outcome Category Grade 1 Grade 2 Grade 3 Grade 4
Subjective Pain Occasional
and minimal, hyper-
sensation, pruritus
Intermittent and tol-
erable
Persistent and in-
tense
Refractory and ex-
cruciating
Objective Oedema Asymptomatic Symptomatic Secondary dysfunc-
tion
-
37Sequencing of chemotherapy and radiotherapy for early breast cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. LENT/SOMA scoring scale (Continued)
Fibrosis Barely palpable, in-
creased density
Definite increased
density and firmness
Very marked
increased density, re-
traction and fixation
-
Telangiectasia < 1 cm2 1 to 4 cm2 > 4 cm2 -
Lymphoedema 2 to 4 cm > 4 to 6 cm > 6 cm Useless arm
Atrophy/retraction 10% to 25% > 25% to 40% > 40% to 75% Whole breast
Ulcer Epidermal only ≤ 1
cm2
Dermal > 1 cm Subcutaneous Bone exposed/
necrosis
Management Pain Occasional, non-
narcotic
Regular narcotic Regular
narcotic medical in-
tervention
Surgical
intervention
Oedema - - Medical
intervention
Surgical interven-
tion/mastectomy
Lymphoedema arm - Elevate arm, elastic
stocking
Compression wrap-
ping, intensive phys-
iotherapy
Surgical interven-
tion/amputation
Atrophy - Surgical interven-
tion/mastectomy
Ulcer - Medical
intervention
Surgical interven-
tion/debridement
Surgical interven-
tion/mastectomy
Analytic Photographic assess-
ment of skin change
Yes/no Date: - -
Tape measurement
of breast size and
arm diameter
Yes/no Date: - -
Mammogramassess-
ment of skin thick-
ness and density
Yes/no Date: - -
Yes/no Date: computer to-
mog-
raphy/magnetic res-
onance imaging as-
sessment of size, fat
atrophy, fibrosis
Yes/no Date: - -
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Table 3. Pigmentation scoring scale
Pigmentation scoring scale
Excellent
Good
Moderate
Poor
Very poor
Table 4. Harris’s classification modified by Beadle cosmetic scale
Cosmetic score
Excellent
Good
Acceptable
Poor
Very poor
Table 5. LENT-SOMA cosmetic outcome assessment
Category Description
Very poor Very marked density, retraction, fixation and breast asymmetry 40% to 75%
Poor Marked distortion of nipple, breast asymmetry 25% to 40%, marked contour difference, severe hyperpigmentation,
severe oedema, marked mammillary deviation
Acceptable Moderate distortion of nipple, absent nipple-areola complex, breast asymmetry 10% to 25%, telangiectasia, moderate
hyperpigmentation, increased density and firmness, slight oedema, prominent scar with surrounding retraction/volume
loss, moderate contour difference, moderate mammillary deviation
Good Minimal differences between treated and untreated breast, slight distortion of nipple, mild hyperpigmentation, breast
asymmetry < 10%, mild telangiectasia
Very good Treated breast looks almost identical to untreated breast, perfect symmetry, no visible distortion
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Table 6. Acute toxicity: concurrent versus sequential
Type of toxicity Trials Concurrent Sequential OR (95% CI)
Anaemia ARCOSEIN 111/352 81/358 1.54 (1.10 to 2.15)
Grade II/IV skin ARCOSEIN 13/107 11/107 1.21 (0.51 to 2.83)
Grade III/IV infection ARCOSEIN 1/107 3/107 0.33 (0.03 to 3.20)
Grade III/IV neutrope-
nia
ARCOSEIN 19/107 25/107 0.71 (0.36 to 1.38)
Nausea or vomiting ARCOSEIN 235/352 248/343 0.77 (0.56 to 1.06)
Grade III/IV oesophagi-
tis
ARCOSEIN 3/107 0/107 7.20 (0.37 to 141.12)
CI: confidence interval; OR: odds ratio.
Table 7. Late Grade III/IV toxicity: concurrent versus sequential
Toxicity type Study Concurrent Sequential OR (95% CI)
Atrophy ARCOSEIN 19/107 10/107 2.09 (0.92 to 4.75)
Telangiectasia ARCOSEIN 17/107 5/107 3.85 (1.37 to 10.87)
Fibrosis ARCOSEIN 6/107 0/107 13.77 (0.77 to 247.54)
Lymphoedema ARCOSEIN 2/107 1/107 2.02 (0.18 to 22.61)
Pigmentation ARCOSEIN 12/105 1/106 13.55 (1.73 to 106.19)
CI: confidence interval; OR: odds ratio.
Table 8. Late toxicity (cosmesis): concurrent versus sequential
Cosmetic outcome Study Concurrent Sequential Physician-reported
OR (95% CI)
Participant-reported
OR (95% CI)
Bad or very bad
overall cosmesis
ARCOSEIN Physician 43/107
Participant 9/107
Physician 16/107
Participant 8/107
3.82 (1.98 to 7.37) 1.14 (0.42 to 3.07)
Poor/very poor skin
colour
ARCOSEIN Physician 14/107
Participant 3/107
Physician 1/107
Participant 1/107
15.96 (2.06 to 123.
68)
3.06 (0.31 to 29.87)
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Table 8. Late toxicity (cosmesis): concurrent versus sequential (Continued)
Poor/very poor scar ARCOSEIN Physician 24/107
Participant 17/107
Physician 15/107
Participant 12/107
1.77 (0.87 to 3.61) 1.50 (0.68 to 3.31)
CI: confidence interval; OR: odds ratio.
Table 9. Acute toxicity: RT then CT versus CT then RT
Toxicity type Study RT then CT CT then RT OR (95% CI)
Neutropenic sepsis Bellon 2005 21/122 8/122 2.96 (1.26 to 6.98)
Pneumonia 6/122 1/122 6.26 (0.74 to 52.79)
Haemoglobin (CTC
Grade III/IV)
3/114 4/120 0.78 (0.17 to 3.58)
Platelet (CTCGrade III/
IV)
0/114 3/120 0.15 (0.01 to 2.87)
Skin (CTC Grade III/
IV)
17/115 12/112 1.45 (0.66 to 3.18)
CI: confidence interval; CT: chemotherapy; CTC: common toxicity criteria; OR: odds ratio; RT: radiotherapy.
Table 10. Late toxicity: RT then CT versus CT then RT
Toxicity type Study RT then CT CT then RT OR (95% CI)
Pneumonitis Bellon 2005 5/122 0/122 11.47 (0.63 to 209.70)
Cosmesis 26/39 23/38 1.30 (0.51 to 3.31)
Cardiac 0/113 0/118
Cellulitis 6/117 3/119 2.09 (0.051 to 8.56)
Lymphoedema 8/117 4/119 2.11 (0.67 to 7.21)
Brachial plexopathy 1/42 0/43 3.14 (0.12 to 79.39)
CI: confidence interval; CT: chemotherapy; OR: odds ratio; RT: radiotherapy.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. RANDOMIZED CONTROLLED TRIAL.pt
2. CONTROLLED CLINICAL TRIAL.pt
3. RANDOMIZED CONTROLLED TRIALS.sh
4. RANDOM ALLOCATION.sh
5. DOUBLE BLIND METHOD.sh
6. SINGLE BLIND METHOD.sh
7. 1 or 2 or 3 or 4 or 5 or 6
8. (ANIMALS not HUMAN).sh
9. 7 not 8
10. CLINICAL TRIAL.pt
11. exp CLINICAL TRIALS/
12. (clin$ adj25 trial$).ti,ab
13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab
14. PLACEBOS.sh
15. placebo$.ti,ab
16. random$.ti,ab
17. RESEARCH DESIGN.sh
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 18 not 8
20. 19 not 9
21. 9 or 20
22. Breast Neoplasms.me
23. breast cancer.ti,ab,sh,kw
24. breast tumour.ti,ab,sh,kw
25. Mamm$ near Carcinoma.kw,sh,sb
26. Carcinoma, Ductal, Breast.mp
27. 22 or 23 or 24 or 25 or 26
28. Chemotherapy, adjuvant.me
29. adjuvant chemotherapy.kw,sh,ti,ab
30. Antineoplastic Combined Chemotherapy Protocols
31. Breast Neoplasms/dt
32. cyclophosphamide/tu
33. Doxorubicin/tu
34. Methotrexate/tu
35. fluorouracil/tu
36. Carcinoma, Ductal, Breast/dt
37. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. radiotherapy, adjuvant.me
39. radiotherapy.sh,kw,ti,ab
40. radiation therapy.sh,kw,ti,ab
41. Breast Neoplasms/rt
42. Carcinoma, Ductal, Breast/rt
43. 38 or 39 or 40 or 41 or 42
44. exp MASTECTOMY, SUBCUTANEOUS/
45. exp MASTECTOMY, MODIFIED RADICAL/
46. mastectomy.mp
47. exp MASTECTOMY, EXTENDED RADICAL/
48. exp MASTECTOMY, SEGMENTAL/
49. MASTECTOMY, RADICAL/
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50. exp MASTECTOMY/
51. exp MASTECTOMY, SIMPLE
52. Breast neoplasms/su
53. mastectomy.kw,ab,ti,sh.
54. lumpectomy.kw,ab,ti,sh
55. wide local excision.kw,ab,ti,sh
56. quadrantectomy.kw,ab,ti,sh.
57. Neoplasm Recurrence, Local/su
58. 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56
59. 21 and 27 and 37 and 43 and 58
Appendix 2. EMBASE search strategy
#45
#44 AND [humans]/lim AND [embase]/lim AND [2008-2011]/py
#44
#8 AND #20 AND #28 AND #32 AND #43
#43
#33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42
#42
’quadrantectomy’/exp OR quadrantectomy
#41
wide AND local AND (’excision’/exp OR excision)
#40
’lumpectomy’/exp OR lumpectomy
#39
simple AND (’mastectomy’/exp OR mastectomy)
#38
modified AND (’radical’/exp OR radical) AND (’mastectomy’/exp OR mastectomy)
#37
’radical’/exp OR radical AND (’mastectomy’/exp OR mastectomy)
#36
segmental AND (’mastectomy’/exp OR mastectomy)
#35
extended AND (’radical’/exp OR radical) AND (’mastectomy’/exp OR mastectomy)
#34
’subcutaneous’/exp OR subcutaneous AND (’mastectomy’/exp OR mastectomy)
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(Continued)
#33
’mastectomy’/exp OR mastectomy
#32
#29 OR #30 OR #31
#31
’radiation’/exp OR radiation AND (’therapy’/exp OR therapy)
#30
’adjuvant’/exp OR adjuvant AND (’radiotherapy’/exp OR radiotherapy)
#29
’radiotherapy’/exp OR radiotherapy
#28
#21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27
#27
’fluorouracil’/exp OR fluorouracil
#26
’methotrexate’/exp OR methotrexate
#25
’doxorubicin’/exp OR doxorubicin
#24
’cyclophosphamide’/exp OR cyclophosphamide
#23
antineoplastic AND combined AND (’chemotherapy’/de OR chemotherapy) AND protocols
#22
’adjuvant’/exp OR adjuvant AND (’chemotherapy’/exp OR chemotherapy)
#21
’chemotherapy’/exp OR chemotherapy
#20
#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19
#19
early NEAR/6 breast AND tumor*
#18
early NEAR/6 breast AND tumour*
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(Continued)
#17
early NEAR/6 breast AND carcinoma*
#16
early NEAR/6 breast AND neoplas*
#15
early NEAR/6 breast AND cancer*
#14
locally AND advance* NEAR/6 breast AND tumor*
#13
locally AND advance* NEAR/6 breast AND tumour*
#12
locally AND advance* NEAR/6 breast AND carcinoma*
#11
locally AND advance* NEAR/6 breast AND neoplas*
#10
locally AND advance* NEAR/6 breast AND cancer*
#9
’breast’/exp AND ’neoplasm’/exp
#8
#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#7
groups:ab
#6
trial:ab
#5
randomly:ab
#4
placebo:ab
#3
randomi*ed:ab
#2
controlled AND clinical AND trial
45Sequencing of chemotherapy and radiotherapy for early breast cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#1
randomised AND controlled AND trial
Appendix 3. CINAHL search strategy
S1. (MH ”Clinical Trials+)
S2. PT Clinical trial
S3. TX clini* n1 trial*
S4. TX ((singl* n1 blind*) or (singl* n1 mask**))
S5. TX randomi* control* trial*
S6. (MH “Random Assignment”)
S7. TX random* allocat*
S8. TX placebo*
S9. (MH “Placebps”)
S10. (MH “Quantitative Studies”)
S11. TX allocat* random*
S12. S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S13. (MH “Breast Neoplasms+”)
S14. (TI breast cancer) or (SU breast cancer) or (AB breast cancer)
S15. (TI breast tumour) or (SU breast tumour) or (AB breast tumour)
S16. (SU Mamm* n1 Carcinoma) or (TI Mamm* n1 Carcinoma) or (AB Mamm* n1 Carcinoma)
S17. (MM “CArcinoma, Ducatal, Breast”)
S18. S13 or S14 or S15 or S16 or S 17
S19. (MM “Chemotherapy, Adjuvant)
S20. (Su adjuvant chemotherapy) or (TI adjuvant chemotherapy) or (AB adjuvant chemotherapy)
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(Continued)
S21. Antineoplastic Combined Chemotherapy Protocls
S22. (MH ”BReast Neoplasms +/DH“)
S23. (MH ”Cyclophosphamide+/TU“)
S24. (MH ”Doxorubicin+/TU“)
S25 (MM ”Methotrexate/TU“)
S26. (MM ”Fluorouracil/TU“)
S27. (MM ”Carcinoma, Ductal, Breast/DT“)
S28. S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27
S29. (MM ”Radiotherapy Adjuvant“)
S30. (SU radiotherapy) or (TI radiotherapy) or (AB radiotherapy)
S31. (SU radiation therapy) or (TI radiation therapy) or (AB radiation therapy)
S32. (MH ”Breast Neoplasms+/RT)
S33. (MM “Carcinoma, Ductal, Breast/RT”)
S34. S29 or S30 or S31 or S32 or S33
S35. (MH “Mastectomy+)
S36. ”Mastectomy“
S37. (MM ”Breast Neoplasms/SU“)
S38. (SU mastectomy) or (AB mastectomy) or TI mastectomy)
S39. (SU Lumpectomy) or (AB mastectomy) or (TI mastectomy)
S40. (SU quadrenectomy) or (AB quadrentectomy) or (TI quadrantectomy)
S41. (SU ”wide local excision“) or (AB ”wide local excision“) or (TI ”wide local excision)
S42. (MM “Neoplasm Recurrence, Local”)
S43. S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42
S44. S12 and S18 and S28 and S34 and S42
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Appendix 4. Science Citation Index search strategy
1. (breast near/5 cancer OR breast neoplasms OR breast near/5 tumour OR Mamm near/5 carcinoma) in Topic, AND
2. (chemotherapy OR cyclophosphamide OR duxorubicin OR methotrexate OR fluorouracil OR radiotherapy OR radi* therapy) in
Topic, AND
3. (Mastectomy OR radical mastectomy OR lumpectomy OR quadrenectomy OR wide local excision) in Topic
Appendix 5. WHO ICTRP search strategy
Advanced search:
1. Title: Sequencing of chemotherapy and radiation therapy for early breast cancer
Recruitment Status: ALL
2. Condition: breast cancer%
Intervention: (chemotherapy OR adjuvant chemotherapy OR Antineoplastic Combined Chemotherapy Protocols OR Cyclophospha-
mide OR Doxorubicin OR Methotrexate OR Fluorouracil) AND (radiotherapy OR adjuvant radiotherapy OR radiation therapy)
AND (mastectomy OR lumpectomy OR quadrantectomy)
Recruitment Status: ALL
3. Condition: locally advanced breast cancer%
Intervention: (chemotherapy OR adjuvant chemotherapy OR Antineoplastic Combined Chemotherapy Protocols OR Cyclophospha-
mide OR Doxorubicin OR Methotrexate OR Fluorouracil) AND (radiotherapy OR adjuvant radiotherapy OR radiation therapy)
AND (mastectomy OR lumpectomy OR quadrantectomy)
Recruitment Status: ALL
4. Condition: early breast cancer%
Intervention: (chemotherapy OR adjuvant chemotherapy OR Antineoplastic Combined Chemotherapy Protocols OR Cyclophospha-
mide OR Doxorubicin OR Methotrexate OR Fluorouracil) AND (radiotherapy OR adjuvant radiotherapy OR radiation therapy)
AND (mastectomy OR lumpectomy OR quadrantectomy)
Recruitment Status: ALL
WH A T ’ S N E W
Last assessed as up-to-date: 20 May 2011.
Date Event Description
17 January 2012 New citation required but conclusions have not changed Further data for included studies added, involving 313
patients. Full risk of bias tables added. Conclusions re-
main unchanged
20 May 2011 New search has been performed Performed search for new studies on 20 May 2011.
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H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 4, 2006
Date Event Description
14 August 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
BH and ML both contributed to writing the protocol, data extraction, analysis and writing of the discussion.
DF wrote the search strategy for the initial version, as well as in the update, and contributed to data extraction, analysis and writing of
the paper.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Princess Alexandra Hospital Cancer Collaborative Group, Australia.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have reported the late effect cosmesis (where available) although we did not specify that we would do so in our protocol. Where
information has allowed us to present HRs, we have done so.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Anemia [etiology]; Breast Neoplasms [∗drug therapy; mortality; ∗radiotherapy; surgery]; Chemotherapy, Adjuvant [adverse effects;
∗methods]; Pigmentation Disorders [etiology]; Radiotherapy, Adjuvant [adverse effects; ∗methods]; Randomized Controlled Trials as
Topic; Telangiectasis [etiology]; Time Factors
MeSH check words
Female; Humans
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